{"nctId":"NCT00827983","briefTitle":"Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Patients Undergoing In-Vitro Fertilization (IVF)","startDateStruct":{"date":"2009-01"},"conditions":["In Vitro Fertilization"],"count":683,"armGroups":[{"label":"Progesterone SC","type":"EXPERIMENTAL","interventionNames":["Drug: Progesterone"]},{"label":"Progesterone Vaginal gel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Progesterone"]}],"interventions":[{"name":"Progesterone","otherNames":[]},{"name":"Progesterone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18- 42 (upon starting COH);\n* BMI \\<30 kg/m2;\n* \\<3 prior ART cycles (IVF, ICSI and related procedures);\n* Baseline (day 2-3 of cycling) FSH \\<15 IU/L and E2 \\<80 pg/mL;\n* Normal uterine cavity as per recent hysterosalpingogram, sonohysterogram or hysteroscopic exam (i.e. no polyp or protruding sub-mucosal fibroid);\n* At least 3 retrieved oocytes;\n* Patient has given written informed consent.\n\nExclusion Criteria:\n\n* Intramural uterine fibroids that distort the uterine cavity or polyps \\>1 cm;\n* Stage III or IV endometriosis (endometriomas);\n* Hydrosalpinx;\n* History of past poor response to COH resulting in canceling ART;\n* Use of thawed/donated oocytes;\n* Use of thawed/donated embryos;\n* Patients affected by pathologies associated with any contraindication of being pregnant;\n* Hypersensitivity to study medication;\n* Uncontrolled adrenal or thyroid dysfunction;\n* Undiagnosed vaginal bleeding;\n* History of arterial disease;\n* Patients with hepatic impairment;\n* Neoplasias (current) or history of neoplasia that may be responsive to progesterone;\n* High grade cervical dysplasia;\n* Active thrombophlebitis or thromboembolic disorders, or a history of hormone-associated thrombophlebitis or thromboembolic disorders;\n* History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages wherein pregnancy developed to a minimum of a gestational sac on TVUS;\n* Participation in a concurrent clinical trial or another trial within the past 2 months;\n* Use of concomitant medications that might interfere with the study evaluation;\n* Pre-implantation genetic diagnosis/screening.","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"42 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ongoing Pregnancy Rate at the End of the Study","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.4","spread":null},{"groupId":"OG001","value":"30.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Delivery Rate and Live Birth Rate","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"29.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Implantation Rate","description":"Implantation rate was defined as the mean of the total number of gestational sacs seen divided by the total number of embryos transferred. Values are reported as a percentage.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":"35.0"},{"groupId":"OG001","value":"23.1","spread":"33.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":338},"commonTop":["Administration site pain","vaginal hemorrage","Uterine spasm","Administration site pruritus","vaginal discharge"]}}}